Table 3.
Comparison of percentages (with IQR) of positivity of TIGIT on γδ T cells in patients with AMLy-DN and HIs.
| HIs | DN | CR | p-value | |||
|---|---|---|---|---|---|---|
| DN vs. HIs | DN vs. CR | CR vs. HIs | ||||
| TIGIT+ γδ | 17.85 (7.92, 26.98) | 35.30 (23.58, 57.38) | 17.60 (12.05, 34.83) | <0.001 | 0.014 | 0.614 |
| TIGIT+ TCM γδ | 5.26 (2.94, 12.65) | 25.55 (15.65, 36.28) | 10.65 (6.64, 23.58) | <0.001 | 0.013 | 0.045 |
| TIGIT+ TEM γδ | 6.04 (2.82, 11.18) | 16.10 (4.67, 22.63) | 12.55 (6.91, 16.70) | 0.029 | 0.420 | 0.115 |
| TIGIT+ TEMRA γδ | 48.85 (29.18, 76.40) | 77.20 (55.15, 90.90) | 57.00 (34.95, 66.28) | 0.034 | 0.078 | 0.930 |
DN, patients with newly diagnosed AML under 65 years; CR, patients with AML with complete remission; HIs, healthy individuals.